Navigation Links
Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences
Date:8/31/2011

WALTHAM, Mass., Aug. 31, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that management will present at the following upcoming fall financial conferences:

  • Robert W. Baird Healthcare Conference, New York, NY, September 8 at 8:30 AM ET
  • Sach's 11th Annual Biotech in Europe Investor Forum, Zurich, Switzerland, September 13, 11:15 AM CEST oncology panel and 12:15 PM CEST corporate presentation
  • UBS Global Life Sciences Conference, New York, NY, September 19 at 4:00 PM ET
  • Sofinnova BioPartnering Conference 2011, Tokyo, Japan, October 4, time to be determined.  Please visit http://www.sofinnovajapanpartnering.com/program.php for the schedule.
  • 10th Annual BIO Investor Forum, San Francisco, CA, October 25 to 26, exact date and time to be determined.  Please visit http://www3.bio.org/investorforum/presenting-companies/2011/ for the schedule.

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.  Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.  For more information please visit www.syndax.com.

Contact Information
E. Blair Schoeb
Syndax Pharmaceuticals, Inc
Tel: 908-277-0386
bschoeb@syndax.com


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
2. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
3. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
4. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
5. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
6. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
7. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
8. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
9. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
10. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
11. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):